Lansoprazol Teva

Lansoprazole, the active ingredient in Lansoprazol Teva, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is used to treat conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication regimens, and Zollinger‑Ellison syndrome.\n\nGNH India supplies Lansoprazol Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor that lowers gastric acidity in several acid‑related disorders.\n\nGastro‑oesophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of esophageal irritation.\nPeptic ulcer disease: facilitates ulcer healing by decreasing gastric acid exposure.\nHelicobacter pylori eradication regimens: enhances the effectiveness of antibiotic combinations used to eradicate H. pylori.\nZollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.

Lansoprazol Teva may cause a range of adverse reactions.\n\nCommon Side Effects:\n- Headache\n- Diarrhoea\n- Abdominal pain\n- Nausea\n\nSerious or Rare Side Effects:\n- Severe allergic reaction (anaphylaxis)\n- Low magnesium levels (hypomagnesemia)\n- Clostridioides difficile‑associated colitis

When prescribing Lansoprazol Teva, clinicians should consider several safety measures.\n\nAssess renal function: adjust use in patients with severe renal impairment.\nMonitor magnesium levels: especially during long‑term therapy.\nAvoid concomitant use with strong CYP2C19 inhibitors unless necessary.\nUse caution in patients with liver disease: dose may need adjustment.\nStore at ambient temperature: keep in original container, protect from moisture.

Lansoprazol Teva can interact with a variety of medicines, requiring attention to the interaction strength.\n\nMajor Interactions (Avoid):\n- Ketoconazole: reduced absorption of ketoconazole.\n- Atazanavir: decreased effectiveness of atazanavir.\n- Clopidogrel: reduced activation of clopidogrel.\n\nModerate Interactions (Monitor Closely):\n- Warfarin: may increase INR.\n- Digoxin: may raise serum digoxin levels.\n- Methotrexate: may increase methotrexate toxicity.